ArticleEuropean journal of trauma & dissociation = Revue europeenne du trauma et de la dissociation2025
Self-Reported Improvements in Comorbid Post-Traumatic Stress Disorder Symptoms, Depression, Anxiety, and Sleep Among Real-World Patients Receiving Medical Ketamine: Exploring the Role of Adjunct Therapies.
Article in European journal of trauma & dissociation = Revue europeenne du trauma et de la dissociation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A scoping review: ketamine or esketamine when used to assist psychotherapy or in combination with psychotherapy for the management of depression in adults.Npj mental health research · 2026Article
- Treating chronic pain with low dose ketamine and adjunct therapies within a biopsychosocial approach: a case series.Frontiers in pain research (Lausanne, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Introduction: Post-traumatic stress disorder (PTSD) presents severe symptomology and often co-occurs with depression, warranting novel treatment approaches to address both conditions simultaneously. Ketamine has emerged as a rapid antidepressant and potential treatment for PTSD, with some real-world evidence for effectiveness regardless of comorbidities. The purpose of this secondary analysis was to explore the perceived and self-reported outcomes of ketamine treatment in real-world patients with comorbid PTSD. Methods: In an anonymous online survey with quantitative and qualitative items, real-world patients ( Results: Participants with comorbid PTSD ( Discussion: As perceived by real-world patients, ketamine successfully improved an array of symptoms and allowed reprocessing of the trauma. Targeted longitudinal and qualitative research is needed in larger, more diverse samples on the role and effects of other adjunct psychological and somatic therapies to inform and optimize PTSD treatment protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.